181 related articles for article (PubMed ID: 19769966)
1. The cell senescence inducing gene product MORF4 is regulated by degradation via the ubiquitin/proteasome pathway.
Tominaga K; Tominaga E; Ausserlechner MJ; Pereira-Smith OM
Exp Cell Res; 2010 Jan; 316(1):92-102. PubMed ID: 19769966
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease.
van Tijn P; de Vrij FM; Schuurman KG; Dantuma NP; Fischer DF; van Leeuwen FW; Hol EM
J Cell Sci; 2007 May; 120(Pt 9):1615-23. PubMed ID: 17405812
[TBL] [Abstract][Full Text] [Related]
3. Rapid turnover of GATA-2 via ubiquitin-proteasome protein degradation pathway.
Minegishi N; Suzuki N; Kawatani Y; Shimizu R; Yamamoto M
Genes Cells; 2005 Jul; 10(7):693-704. PubMed ID: 15966900
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor gamma and retinoid X receptor alpha in human keratinocytes.
Boudjelal M; Wang Z; Voorhees JJ; Fisher GJ
Cancer Res; 2000 Apr; 60(8):2247-52. PubMed ID: 10786691
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics.
Yang Y; Kitagaki J; Dai RM; Tsai YC; Lorick KL; Ludwig RL; Pierre SA; Jensen JP; Davydov IV; Oberoi P; Li CC; Kenten JH; Beutler JA; Vousden KH; Weissman AM
Cancer Res; 2007 Oct; 67(19):9472-81. PubMed ID: 17909057
[TBL] [Abstract][Full Text] [Related]
6. Deubiquitination by proteasome is coordinated with substrate translocation for proteolysis in vivo.
Zhu Q; Wani G; Wang QE; El-mahdy M; Snapka RM; Wani AA
Exp Cell Res; 2005 Jul; 307(2):436-51. PubMed ID: 15950624
[TBL] [Abstract][Full Text] [Related]
7. Differential GATA factor stabilities: implications for chromatin occupancy by structurally similar transcription factors.
Lurie LJ; Boyer ME; Grass JA; Bresnick EH
Biochemistry; 2008 Jan; 47(3):859-69. PubMed ID: 18154321
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Alao JP; Stavropoulou AV; Lam EW; Coombes RC; Vigushin DM
Mol Cancer; 2006 Feb; 5():8. PubMed ID: 16504004
[TBL] [Abstract][Full Text] [Related]
9. Activation of hypoxia-induced transcription in normoxia.
Hägg M; Wennström S
Exp Cell Res; 2005 May; 306(1):180-91. PubMed ID: 15878343
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells.
Yang W; Monroe J; Zhang Y; George D; Bremer E; Li H
Cancer Lett; 2006 Nov; 243(2):217-27. PubMed ID: 16413676
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ubiquitin proteasome function suppresses proliferation of pulmonary artery smooth muscle cells.
Li M; Dong X; Liu Y; Sun X; Li Z; He J
Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):517-23. PubMed ID: 21850573
[TBL] [Abstract][Full Text] [Related]
12. Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway.
Gong Q; Keeney DR; Molinari M; Zhou Z
J Biol Chem; 2005 May; 280(19):19419-25. PubMed ID: 15760896
[TBL] [Abstract][Full Text] [Related]
13. cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1.
Hoang T; Fenne IS; Cook C; Børud B; Bakke M; Lien EA; Mellgren G
J Biol Chem; 2004 Nov; 279(47):49120-30. PubMed ID: 15347661
[TBL] [Abstract][Full Text] [Related]
14. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators.
Yan F; Gao X; Lonard DM; Nawaz Z
Mol Endocrinol; 2003 Jul; 17(7):1315-31. PubMed ID: 12663742
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner.
Machiya Y; Hara S; Arawaka S; Fukushima S; Sato H; Sakamoto M; Koyama S; Kato T
J Biol Chem; 2010 Dec; 285(52):40732-44. PubMed ID: 20959456
[TBL] [Abstract][Full Text] [Related]
16. [Artifitial increase of HIV-1 reverse transcriptase turnover through proteasome pathway].
Starodubova ES; Isaguliants MG; Karpov VL
Mol Biol (Mosk); 2006; 40(6):982-8. PubMed ID: 17209425
[TBL] [Abstract][Full Text] [Related]
17. The ubiquitin-activating enzyme E1 as a novel therapeutic target for the treatment of restenosis.
Qin Z; Cui B; Jin J; Song M; Zhou B; Guo H; Qian D; He Y; Huang L
Atherosclerosis; 2016 Apr; 247():142-53. PubMed ID: 26919560
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability.
Latonen L; Moore HM; Bai B; Jäämaa S; Laiho M
Oncogene; 2011 Feb; 30(7):790-805. PubMed ID: 20956947
[TBL] [Abstract][Full Text] [Related]
19. Suppression of autophagy during mitosis via CUL4-RING ubiquitin ligases-mediated WIPI2 polyubiquitination and proteasomal degradation.
Lu G; Yi J; Gubas A; Wang YT; Wu Y; Ren Y; Wu M; Shi Y; Ouyang C; Tan HWS; Wang T; Wang L; Yang ND; Deng S; Xia D; Chen RH; Tooze SA; Shen HM
Autophagy; 2019 Nov; 15(11):1917-1934. PubMed ID: 30898011
[TBL] [Abstract][Full Text] [Related]
20. Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication.
Teale A; Campbell S; Van Buuren N; Magee WC; Watmough K; Couturier B; Shipclark R; Barry M
J Virol; 2009 Mar; 83(5):2099-108. PubMed ID: 19109393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
